Risk factors for grade 3-4 liver enzyme elevation in HIV and hepatitis C coinfected patients on combination antiretroviral therapy

AIDS Patient Care and STDs

Volumn 21, Issue 7, 2007, Pages 469-478

  Chihrin, S ^a   Antoniou, T ^b   Raboud, J ^c,d   Shen, S ^c   Govan, V ^a   Fletcher, D ^a,d   Rachlis, A ^d,e   Kovacs, C ^a,d   Crouzat, F ^a   Tilley, D ^a   Chang, B ^a,d,e   Saskin, R ^f   Loutfy, M R ^a,d,e  

^a MAPLE LEAF MEDICAL CLINIC   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^f INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALANINE AMINOTRANSFERASE; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LIVER ENZYME; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EXPOSURE; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; RISK FACTOR; SIDE EFFECT; UNIVARIATE ANALYSIS;

ADULT; ALANINE TRANSAMINASE; ANTI-RETROVIRAL AGENTS; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; LIVER; LIVER DISEASES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 34547653926     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2006.0113     Document Type: Article

References (24)

1. Palella FJ Jr., Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-860.
2. Benhamou Y, Di Martino V, Bochet M, et al. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: Impact of protease inhibitor therapy. Hepatology 2001;34:283-287.
3. Qurishi N, Kreuzberg C, Luchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003;362:1708-1713.
4. Sulkowski MS. Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. Clin Infect Dis 2004;38( Suppl 2):S90-97.
5. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000;283:74-80.
6. Wit FW, Weverling GJ, Weel J, Jurriaans S, Lange JM. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002;186:23-31.
7. Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents. Washington, D.C., 2006.
8. Saves M, Vandentorren S, Daucourt V, et al. Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998. Groupe dEpidemiologie Clinique de Sida en Aquitaine (GECSA). AIDS 1999;13:F115-121.
9. Nunez M, Lana R, Mendoza JL, Martin-Carbonero L, Soriano V. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001;27:426-431.
10. den Brinker M, Wit FW, Wertheim-van Dillen PM, et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000;14:2895-2902.
11. Cooper CL, Parbhakar MA, Angel JB. Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis 2002;34:1259-1263.
12. Sherman KE, Shire NJ, Cernohous P, et al. Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: Lopinavir-ritonavir versus nelfinavir. Clin Infect Dis 2005;41:1186-1195.
13. Bonfanti P, Ricci E, Penco G, et al. Low incidence of hepatotoxicity in a cohort of HIV patients treated with lopinavir/ritonavir. AIDS 2005;19:1433-1434.
14. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002;346:2039-2046.
15. Canta F, Marrone R, Bonora S, et al. Pharmacokinetics and hepatotoxicity of lopinavir/ritonavir in non-cirrhotic HIV and hepatitis C virus (HCV) co-infected patients. J Antimicrob Chemother 2005;55:280281.
16. Meraviglia P, Schiavini M, Castagna A, et al. Lopinavir/ritonavir treatment in HIV antiretroviral-experienced patients: Evaluation of risk factors for liver enzyme elevation. HIV Med 2004;5:334-343.
17. Da Silva B, King M, Cernohous P, Brun S. Lopinavir/ritonavir (LPV/r) safety, tolerability and efficacy in HIV patients co-infected with hepatitis C and/or hepatits B: review of clinical trials (abstract MoPeB3285). Presented at the XV International AIDS Conference. Bangkok: July 11-16 2004.
18. Gonzalez-Requena D, Nunez M, Jimenez-Nacher I, Gonzalez-Lahoz J, Soriano V. Short communication: Liver toxicity of lopinavir-containing regimens in HIV-infected patients with or without hepatitis C coinfection. AIDS Res Hum Retroviruses 2004;20: 698-700.
19. Servin-Abad L, Molina E, Baracco G, et al. Liver enzymes elevation after HAART in HIV-HCV co-infection. J Viral Hepat 2005;12:429-434.
20. Maida I, Babudieri S, Selvia C, et al. Liver enzyme elevation in hepatitis C virus (HCV)-HIV-coinfected patients prior to and after initiating HAART: Role of HCV genotypes. AIDS Res Hum Retroviruses 2006;22: 139-143.
21. Torti C, Lapadula G, Casari S, et al. Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: Results from the Italian EPOKA-MASTER cohort. BMC Infect Dis 2005;5:58.
22. Torti C, Lapadula G, Puoti M, et al. Influence of genotype 3 hepatitis C coinfection on liver enzyme elevation in HIV-1 positive patients after commencement of a new highly active antiretroviral regimen: Results from the EPOKA-MASTER cohort. J Acquir Immune Defic Syndr 2006;41:180-185.
23. Nunez M, Rios P, Martin-Carbonero L, Perez-Olmeda M, Gonzalez-Lahoz J, Soriano V. Role of hepatitis C genotype in the development of severe transaminase elevation after the introduction of antiretroviral therapy. J Acquir Immune Defic Syndr 2002;30:65-68.
24. Sabin CA. Pitfalls of assessing hepatotoxicity in trials and observational cohorts. Clin Infect Dis 2004; 38(Suppl 2):S56-64.